Related Experiment Videos
Mini-transplantation strategy for solid tumors
1Hematopoietic Stem Cell Transplant/Immunotherapy Unit, National Cancer Center Hospital, Tokyo, Japan.
International Journal of Hematology
|November 15, 2002
Summary
Reduced-intensity stem cell transplantation (RIST) shows promise for both hematological and solid tumors. This approach achieved good donor chimerism and a 70% overall survival rate at one year.
Area of Science:
- Hematology
- Oncology
- Stem Cell Transplantation
Background:
- Reduced-intensity stem cell transplantation (RIST) is an evolving treatment modality.
- RIST regimens aim to balance efficacy with reduced toxicity.
- Application of RIST in solid tumors remains an area of active investigation.
Purpose of the Study:
- To update the outcomes of a phase I RIST program.
- To evaluate RIST in patients with hematological and metastatic solid tumors.
- To highlight challenges and successes in treating solid tumors with RIST.
Main Methods:
- Phase I clinical trial involving 85 patients with hematological (n=68) or solid tumors (n=17).
- RIST regimen included fludarabine or cladribine with busulfan, with or without anti-thymocyte globulin (ATG).
- Peripheral blood stem cell transplantation (PBSCT) utilized HLA-identical or one antigen-mismatched related donors.
Main Results:
- Mild regimen-related toxicities were observed.
- >90% donor chimerism achieved before day 30 in most patients.
- Overall survival at one year was approximately 70% for both hematological and solid malignancies.
Conclusions:
- RIST is a feasible and effective treatment for selected hematological and solid tumors.
- The RIST program demonstrated acceptable toxicity and encouraging survival rates.
- Further research is warranted to optimize RIST for solid tumor treatment.